Clinical Observation Of Tongxinluo Capsule In The Treatment Of Unstable Angina Pectoris And Its Effect On Serum TNF-α And ICAM-1 Level

Purpose:To observe the effect of Tongxinluo capsule on the degree of UAP in patients with unstable angina pectoris(UNSTABLE Angina pectoris,UAP)and the effect of tongxinluo capsule on serum TUMOR necrosis factor α(TNF-α)and intercellular adhesion molecule-1(ICAM-1).To study its clinical effect and treatment mechanism,and provide safe and effective treatment for patients.Material and method:In the current study,80 patients enrolled voluntarily and met the inclusion criteria and were randomly assigned to either the control group(n=40)or the treatment group(n=40).The control group received standardized treatment of modern Western medicine,and the experimental group added Tongxinluo capsule according to the control group.The course of treatment was 35 days.According to the CRF table,angina pectoris score,TCM syndrome score,Pittsburgh sleep quality score(PSQI)and quality of life assessment of the two groups were recorded before and after treatment to analyze the therapeutic effect of unstable angina pectoris.The contents of TNF-α and ICAM-1 in serum were determined by ELISA.Results:1.Angina symptom efficacy: After treatment,the scores of angina pectoris in the two groups were lower than before treatment(P < 0.01),and the degree of angina pectoris was relieved.The total effective rate of the treatment group and the control group was 90% and 82.05%,respectively,and the treatment group was better than the control group(P < 0.01).2.TCM syndrome efficacy:After treatment,the TCM syndrome score of the two groups was lower than that before treatment(P < 0.01),and the TCM syndrome was improved.The total effective rate of the treatment group and the control group was 92.5% and 84.61%,respectively,and the treatment group was better than the control group(P < 0.05).3.Pittsburgh Sleep Quality Score(PSQI): After treatment,the sleep quality was improved in both groups(P < 0.01),and the treatment group was better than the control group(P < 0.05).4.Inflammatory factor levels: After treatment,the levels of TNF-α and ICAM-1 in 2 groups were decreased(P < 0.01),and the treatment group was better than the control group(P <0.05).5.Comparison of safety: None of the groups had serious drug side effects or reported abnormal blood,urine,liver,and kidney function,which were safer with the two treatments.Conclusion:1.Tongxinluo capsule can significantly improve clinical symptoms,TCM syndromes and sleep status of UAP patients with qi deficiency and blood stasis.2.The mechanism of Tongxinluo capsule in the treatment of qi-deficiency and blood-stasis UAP is related to the decrease of serum TNF-α and ICAM-1,so as to reduce the vasoinflammatory response.3.Tongxinluo capsule in the treatment of CHD unstable angina pectoris can not only improve the therapeutic effect,but also has good safety,providing better treatment for patients.